News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Immune Design Corporation (IMDZ) Announces Closing Of Initial Public Offering


7/30/2014 7:42:51 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SEATTLE and SOUTH SAN FRANCISCO, Calif., July 29, 2014 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ) announced today the closing of its initial public offering of 5,000,000 shares, at a public offering price of $12.00 per share, resulting in aggregate gross proceeds of $60.0 million, before underwriting discounts, commissions and expenses.

Jefferies LLC and Leerink Partners LLC acted as joint book-running managers, and Wells Fargo Securities, LLC acted as lead manager for the offering.

A registration statement relating to the common stock being offered and sold by Immune Design was declared effective by the Securities and Exchange Commission on July 23, 2014. The offering was made only by means of a prospectus, copies of which may be obtained by contacting Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 12th Floor, New York, NY 10022, telephone: (877) 547-6340, e-mail: Prospectus_Department@Jefferies.com; or Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at (800) 808-7525, or by email at syndicate@leerink.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Immune Design

Immune Design is a clinical stage immunotherapy company employing next-generation in vivo approaches to enable the body's immune system to fight disease. The company's technologies are engineered to activate the immune system's natural ability to create tumor-specific cytotoxic T cells to fight cancer and other chronic diseases. Immune Design's clinical programs are the product of its two synergistic discovery platforms: DCVexTM and GLAASTM. Immune Design has offices in Seattle, Washington and South San Francisco, California. For more information, visit http://www.immunedesign.com

CONTACT: Contact for Immune Design: Julie Rathbun Rathbun Communications julie@rathbuncomm.com 206.769.9219

company logo


Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES